Introduction
Systemic lupus erythematosus (SLE) is an inflammatory multisystem autoimmune disease characterized by the production of multiple autoantibodies and immune complexes, causing severe multi-organ damage including nephritis and central nervous system disorder. The prognosis of SLE has improved with five-year survival rates greater than 95% presumably due to the advance of effective immunosuppressive therapy and management against infectious complications.
1 Consequently, the major cause of death in SLE has become cardiovascular diseases (CVD) and thrombosis. 2 Nowadays, thrombosis is one of the most frequent complications in patients with SLE, significantly affecting morbidity and mortality. 3 A number of risk factors for thrombosis in SLE patients have been identified. Among them, the presence of antiphospholipid antibodies (aPL), detected in up to half of SLE patients, is a well-documented risk for the occurrence of thrombosis. [4] [5] [6] aPL is a heterogeneous family of autoantibodies with different specificities including lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti-b2-glycoprotein I antibodies (ab2GPI) and phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT). 7, 8 The occurrence of thrombotic events, as well as obstetric complications, in association with the persistent presence of aPL is defined as antiphospholipid syndrome (APS).
Apart from aPL, a number of other risk factors for thrombosis, such as older age at SLE onset, male sex, high disease activity, and obesity, have been reported by some cohort studies. 4, 9, 10 On the other hand, few data are available regarding the primary prevention of thrombosis, although many studies focused on the prevention of recurrent thrombotic events. [11] [12] [13] [14] [15] Statins, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are frequently prescribed for SLE patients to treat dyslipidemia, primary and/or secondary to the use of corticosteroids. These drugs have been proven to be effective also for primary and secondary prevention of CVD and venous thrombosis in some large studies. [16] [17] [18] [19] Based on the in vitro effect of statins on endothelial cells activated by aPL, statins may have some advantages in patients with APS, [20] [21] [22] but other clinical studies have failed to show their benefit. 23 We assumed that the mechanisms and risk factors of thrombosis would be different between SLE patients with and without aPL. The main purpose of this study was to investigate the effects of statins on thrombosis prevention in SLE patients with or without aPL. Moreover, we investigated the risk or protective factors for thromboembolic complications in a cohort of SLE patients
Patients and methods

Patients
Newly diagnosed patients with SLE attending our Rheumatology clinic from April 1997 to February 2014 were consecutively included in this retrospective cohort study. SLE was diagnosed according to the 1997 American College of Rheumatology (ACR) revised criteria for SLE. 24, 25 Patients with a history of thrombosis and those who had received any anti-thrombotic agent prior to or at the time of SLE diagnosis were excluded.
Study design
The primary outcome was to identify the development of the first thrombotic event after inclusion. At the first visit to our clinic, all patients underwent physical and laboratory examination by certified rheumatologists and the diagnosis of SLE was established by ACR criteria. 24, 25 Patients were followed up at our clinic up to June 2014. The occurrences of the first thrombotic events or deaths during the follow-up period were recorded. Arterial thrombosis was defined as cerebral infarction (CIn), acute coronary syndrome, and other internal organ arterial thrombosis such as intestinal infarction, renal infarction. Venous thrombosis comprised deep vein thrombosis (DVT) or pulmonary embolism (PE). Thrombosis should be symptomatic and confirmed by at least one of the following methods: Doppler ultrasound, computed tomographic (CT) scanning, magnetic resonance imaging (MRI), nuclear medicine scan, or histopathology. Brain CT and brain MRI were performed in SLE patients with symptoms suspected of a cerebrovascular attack such as dysarthria, paralysis, disturbance of consciousness, and visual disorders. Hemorrhagic and thrombotic stroke could be distinguished by the different enhancement patterns on brain CT and brain MRI.
To evaluate risk and protective factors, medical records were retrospectively reviewed and the following demographic, clinical, and laboratory data were verified by the authors: age at disease onset, gender, family history of thrombosis, malar rash, discoid rash, photosensitivity, oral ulcers, arthritis, serositis, lupus nephritis (LN), neurological disorder, hemolytic anemia, leukopenia (white blood cell < 4000/mm 3 or lymphocyte < 1500/mm 3 ), thrombocytopenia (platelets < 100,000/mm 3 ), C3, C4, CH50, anti-DNA antibodies, LA, immunoglobulin (Ig)G/IgM-aCL, IgG/IgM-ab2GPI, IgG/ IgM-aPS/PT. Disease activity was evaluated by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). 26 Historical profile of traditional risk factors for thrombosis was evaluated: smoking history, obesity (body mass index > 25 kg/m 2 ), oral contraceptives, hypertension (systolic blood pressure > 140 mm Hg, diastolic blood pressure > 90 mm Hg, or use of antihypertensive drugs at the time of SLE diagnosis), dyslipidemia (total cholesterol > 220 mg/dl, fasting triglycerides > 150 mg/dl, high-density lipoprotein cholesterol < 40 mg/dl, or using lipid-lowering drugs at the time of SLE diagnosis), diabetes mellitus (hemoglobin A1c > 6.5% at baseline or using antidiabetic drugs at the time of SLE diagnosis).
The initiation of new drugs within three months from SLE onset was also analyzed. In our hospital, the specific treatment for newly diagnosed SLE patients is established during the hospitalization period extended up to three months. Therefore, we have included in the analysis the use of medications started within three months from SLE onset. These drugs included corticosteroids, immunosuppressive agents (cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, methotrexate and mizoribine), anti-thrombotic agents (low-dose aspirin, ticlopidine, clopidogrel, dipyridamole, cilostazol, warfarin and heparin), statins and vitamin D (alfacalcidol, calcitriol and eldecalcitol). All of these drugs were prescribed according to the clinicians' judgment.
Detection of aPL
LA was detected according to the previous version of guidelines recommended by the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. 27 For measurement of the activated partial thromboplastin time, a sensitive reagent with low phospholipid concentration (test PTT-LA; Diagnostica Stago) was used for the screening and mixing test, and the results were confirmed with the use of a Staclot LA kit (Diagnostica Stago). The dilute Russell's viper venom time was screened and confirmed by use of a Gradipore LA test (Sydney New South Wales, Australia). The kaolin clotting time was measured using a kaolin solution (Dade Behring, Liederbach, Germany) with the standard protocol. The cut-off levels for the LA tests were previously established as > 99th percentile of 40 healthy individuals, as per our routine laboratory assays. 28 Testing for IgG/IgM-aCL was performed using the standard aCL enzymelinked immunosorbent assay (ELISA). 29 IgG/ IgM-ab2GPI were determined by ELISA, as previously reported. 30 IgG/IgM-aPS/PT were measured by in-house ELISAs, as previously described. 7 Patients were defined as aPL positive if at least one of the tests described above was positive.
The study was performed in accordance with the Declaration of Helsinki and the Principles of Good Clinical Practice. Approval was obtained from the local ethics committee.
Statistical analysis
Continuous variables were expressed as the mean AE standard deviation (SD) if normally distributed, or as the median and quartiles if they had a skewed distribution. Categorical variables were described as counts and percentages. Fisher's exact test, Student's t test or Mann-Whitney U test were carried out appropriately. Kaplan-Meier curves were applied to evaluate the time to first development of thrombosis and event-free survival. Log-rank test was used to compare Kaplan-Meier curves associated with thrombosis. P values less than 0.05 were considered as statistically significant.
In multivariate analysis, variables that had statistical significance (p < 0.05) in the log-rank test were included. Age and sex were entered in the multivariate model, regardless of statistical significance in the univariate analysis. After excluding variables that had strong association with the other variables by Pearson's test, the risk and protective factors for thrombosis were analyzed by multivariate Cox's proportional hazards model. All statistical analyses were performed using SPSS software, version 22.0 (Chicago, IL, USA).
Results
A total of 152 Japanese patients (138 female, 14 male) without previous history of thrombotic events nor use of anti-thrombotic agents were enrolled in the study. Eighty patients had aPL and 72 patients were negative for any aPL tested at baseline. Table 1 shows the baseline characteristics of all patients. Thirteen out of 51 patients positive for LA had aPS/PT (11 had IgG, five IgM and three both IgG/IgM). The median age was 30 (interquartile range (IQR) 22-41) years and 33 (IQR 24-46) years in the aPL-positive and -negative groups, respectively. The median followup periods for the aPL-positive and -negative groups were 69 (IQR 27-118) months and 46 (IQR 25-105), respectively.
As for clinical and laboratory features associated with SLE, such as mucocutaneous disorders, hematological abnormalities, serositis, and neurological involvement, no statistical significances were observed between aPL-positive and -negative patients.
Regarding traditional risk for thrombosis, the prevalence of arterial hypertension was significantly higher in patients negative for aPL (25%) compared with those positive for aPL (10%) (p ¼ 0.018). There were no statistically significant differences in the prevalence of other traditional risk factors between the two groups.
The analysis of treatment started within three months after SLE onset showed that aPL-positive patients were less frequently treated with corticosteroids and immunosuppressive agents than those without aPL (p ¼ 0.018, p ¼ 0.013, respectively). No statistical differences were found in the usage of statin or anti-thrombotic agents between two groups.
The median follow-up period in the whole cohort of SLE patients was 65 (IQR 28-117) months. Twenty-two (14%) patients developed thrombosis; 15 (19%) in the aPL-positive group and seven (9.7%) in the aPL-negative group. Nine (11%) patients with aPL vs. two (2.8%) patients without aPL had venous thrombosis (p ¼ 0.059, log-rank test), and six (7.5%) patients with aPL vs. five (6.9%) patients without aPL had arterial thrombosis (p ¼ 0.998). In the aPL-positive group, CIn was observed in six (7.5%) patients, DVT alone in four (5.0%), PE alone in three (3.8%), and both DVT and PE at the same time in two (2.5%). In the aPL-negative group, CIn was found in four (5.6%) patients, intestinal infarction in one (1.4%), DVT alone in one (1.4%) and PE alone in one (1.4%). The median periods for the occurrence of thrombosis after SLE diagnosis were 6.0 (IQR 1.5-63) months for the aPL-positive group and 2.0 (IQR 0.5-10) months for the aPL-negative group.
Thirteen thrombotic events occurred within one year from the diagnosis of SLE. Among patients with those early thromboses, eight events occurred in the aPL-positive group and five in the aPL-negative group. Furthermore, nine (aPL positive in five and negative in four) and 13 patients (aPL positive in 10 and negative in three) developed thrombosis within and after three months from SLE onset, respectively. The incidence rate of thrombosis in the aPL-positive and -negative group was 2.92 per 100 patient-years and 1.78 per 100 patient-years, respectively. During the observational period, 34 patients (22%) were lost to follow-up. The median follow-up period was 42 (IQR 12-87) months. Eight patients were lost within the first year from enrollment and 15 patients were lost from the first to fifth years of follow-up. Further, three out of the 34 patients died from infection, liver failure and suicide at two, eight and 18 months after starting follow-up, respectively. There was no death related to thrombosis. Table 2 shows the characteristics of patients divided into four groups, with or without thrombosis and aPL positive or negative during the follow-up period. Results of log-rank analysis in the four groups are shown in Table 3 . When analyzing the clinical manifestations in the aPL-positive group, log-rank analysis revealed that aPL-positive patients who developed thrombosis had a lower frequency of LN (n ¼ 3, 20%) than those without thrombosis (n ¼ 32, 49%) (p ¼ 0.024). In the aPL-negative group, log-rank test indicated that age at SLE onset (every 10 years of age) was significantly increased in the thrombosis group (p ¼ 0.002). The frequency of hypertension was significantly higher in patients with thrombosis (four of seven: 57%) than in those without (14/65: 22%) (p ¼ 0.034). The relationship between aPL profiles and thrombosis was also analyzed. IgG-aCL-positive status was found in five out of 15 (33%) patients who developed thrombosis but in only seven out of 65 (11%) patients without thrombosis (p ¼ 0.003). The frequency of IgG-ab2GPI was higher in patients with thrombosis (p ¼ 0.043). The other aPL evaluated in this study (LA, IgM-aCL, IgMab2GPI, IgG/IgM-aPS/PT) were not identified as risk factors for thrombosis. The use of corticosteroids, immunosuppressive agents, anti-thrombotic drugs or vitamin D within three months from the disease onset was not related to the occurrence of thrombosis in SLE patients with or without aPL.
In this study, 46 patients received statins during three months following the diagnosis of SLE. The relationship between subsequent thrombotic events and statin therapy is shown in Figure 1 . In aPL-positive patients, one out of 15 (6.7%) patients with thrombosis and 22 out of 65 (34%) patients 
>5. (Figure 2) . Moreover, statin therapy played a protective role in developing thrombosis (HR 0.12, 95% CI 0.01-0.98). In patients without aPL, age at SLE onset, hypertension and gender were included in the multivariate analysis. None of these risk factors was correlated with the development of thrombosis.
Analysis according to the criteria aPL
Currently, aPS/PT are frequently found in APS patients but are not yet included in the APS laboratory criteria. We have also analyzed the efficacy of statins in aPL-positive patients defined according to the criteria for aPL, and therefore excluding aPS/ PT.
Seventy-six out of 152 SLE patients had aPL according to APS criteria. 8 During 69 (IQR 27-118) months, 14 patients developed thrombosis. Log-rank analysis revealed that the frequency of LN was lower in patients with thrombosis (p ¼ 0.017), and that the frequencies of IgG-aCLpositive and IgG-ab2GPI-positive status were higher in the thrombosis group (p ¼ 0.001, p ¼ 0.036, respectively). Statin treatment significantly reduced the incidence of thrombosis (p ¼ 0.041) (Supplementary Figure 1) . However, multivariate analysis indicated that statin therapy did not prevent the development of thrombosis (HR 0.16, 95% CI 0.02-1.30).
Discussion
In the present study, we showed that older age at SLE onset and IgG-aCL are risks for subsequent thrombosis in newly diagnosed SLE patients with aPL. More important, we found that the initiation of statins within three months of SLE onset reduced the risk of developing thrombosis, suggesting statins as a potential candidate for primary prophylaxis in early SLE patients positive for aPL.
The relationship between older age at SLE onset and thrombotic risk has been examined in largecohort studies. The LUpus in MInorities: NAture vs nurture (LUMINA) study, a multiethnic longitudinal study of outcome, demonstrated that older age at disease onset was a risk factor for arterial and venous thrombosis. 9, 31 Moreover, Kaiser et al. confirmed these findings in a very large cohort of 1930 SLE patients. 32 The present study supports the published evidence demonstrating that older age at SLE onset represents a risk for thrombosis development. Statin effects for thrombosis in SLE with aPL T Watanabe et al.
It has been already well recognized that aPL increases the risk for thrombosis in SLE. [32] [33] [34] In our study, the incidence rate of thrombosis in SLE patients with and without aPL was 19% and 9.7%, respectively. Similar results were observed in another cohort study reported by Tektonidou et al., in which the thrombosis rates were 20.1% for aPLpositive and 7.6% for aPL-negative patients. 10 We focused on the presence of aPL rather than on the APS diagnosis and included aPS/PT in the definition of aPL positive. Although aPS/PT have not been included in the APS criteria yet, several reports showed that aPS/PT are highly prevalent in APS patients and strongly correlate with LA and thrombosis. 7 Regarding aPL profile related to thrombosis, presence of LA or aCL in SLE patients elevates the risk for arterial and venous thrombosis. 10, 32, 34, 35 In concordance with previous reports, our study showed that IgG-aCL are associated with thrombosis. On the other hand, we could find neither LA nor aPS/PT as a thrombotic risk in our cohort. LA was more prevalent in our newly diagnosed SLE patients compared with other studies. SLE patients have massive polyclonal B-cell activation with production of multiple autoantibodies at onset, and standard corticosteroid/immunosuppressive therapy downregulate such activation of autoantibody production. LA comprises heterogeneous populations of aPL with major and minor anticoagulant functions, thus a number of non-specific LA can be found in new and active SLE patients before immunosuppression. In fact, 64% of our patients had LA, more frequent than more specific aPL such as aCL, ab2GPI or aPS/PT. We do not intend to exclude the role of LA in clinical practice, but such characteristics of LA in immunologically very active SLE patients should be clarified in the near future. The frequency of aPS/PT in our thrombotic patients tended to be higher than in non-thrombotic individuals, although the difference was not statistically significant. It may be due to the study sample size.
The present study shows that thrombosis tends to occur within the first year of disease regardless of the presence or absence of aPL. Previous reports indicated that the incidence of thrombosis increased in the first year following SLE diagnosis. 36, 37 Plausible explanations of early thrombosis may include high disease activity, inflammatory states and the initiation of corticosteroid treatment. 9, 36, 38 The frequency of venous thrombosis appeared to be higher in the aPL-positive group than in the aPL-negative group. However, the incidence of Statin effects for thrombosis in SLE with aPL T Watanabe et al.
arterial or venous thrombosis in each group was too small to conduct statistical subgroup analyses. Although thrombosis is a common and critical manifestation in SLE patients with aPL, few studies have addressed the primary prophylaxis for thrombosis. Some reports described that low-dose aspirin reduced the risk of thrombosis in SLE patients with aPL. 10, 39 In contrast, a prospective study reported by Erkan et al. showed that administration of lowdose aspirin for aPL-positive individuals without a history of thrombosis, including SLE patients, was not beneficial for primary prevention of thrombosis. 40 Therefore, the protective effect of low-dose aspirin as primary prophylaxis for thrombosis is still controversial. Other studies reported that hydroxychloroquine had a beneficial role for primary prophylaxis. 10, 41 However, limited studies have shown the primary anti-thrombotic effect in clinical practice of SLE, although hydroxychloroquine is routinely used in SLE patients. 23 In our study, statin treatment was demonstrated to be effective to decrease the risk of developing thrombotic events in SLE patients with aPL. The main pharmacological effect of statins is to lower serum cholesterol levels, reducing atherosclerosis and CVD events resulted from atherosclerosis. The ''pleiotropic effects'' of statins have been recognized, 19, 42 and some clinical studies successfully revealed their anti-thrombotic effects. [43] [44] [45] [46] Although some works elucidated the preventive effects of statin therapy in SLE-related atherosclerosis, a meta-analysis of randomized controlled trials showed that statins could not improve the atherosclerosis in SLE patients. 47 Our study revealed that statins could reduce the occurrence of thrombosis in patients with aPL but not in those without aPL, indicating that statins might have other anti-thrombotic mechanisms in SLE patients with aPL not related to the prevention of atherosclerosis. A number of experimental studies have shown that statins downregulate the most fundamental procoagulant function of aPL. Statins reduced production of tissue factor (TF), intracellular adhesion molecule-1 (ICAM-1) and interleukin-6 induced by aPL in human umbilical vein endothelial cells. 20, 21 An in vivo study showed that treatment with fluvastatin of APS model mice decreased the size of thromboses and soluble ICAM-1 level. 48 Lo´pez-Pedrera et al. demonstrated the in vivo effect of statins in reducing procoagulant molecule expression. 22 Another clinical study strengthened the evidence of statin effects for aPL-positive patients using biomarkers of thrombin generation. 49 Although statin treatment reduces aPL-induced procoagulant factors both in vitro and in vivo, clinical benefits have not been shown in any study so far. A task force report at the 14th International Congress on aPL concluded that it is difficult to establish the evidence of statin treatment for primary prevention of thrombosis because a large number of patients and long-term follow-up time will be necessary to find statistically significant differences between current treatment and new statin therapeutic approaches. 23 Vitamin D deficiency and insufficiency are related to thrombotic manifestation in APS. The administration of vitamin D had been expected to decrease the development of thrombosis. 23 Contrary to our expectation, this study could not verify the anti-thrombotic effect of vitamin D in SLE patients. The lack of anti-thrombotic effect of vitamin D in our cohort may be explained by the small number of patients included in the study.
Our study certainly had some limitations. This is a single-center-based retrospective observational study, all patients are Japanese, and the number of patients is small so that the results might not be generalized. Additionally, biomarkers associated with thrombosis were not available and the mechanisms of a protective effect of statin for thrombosis are obscure. Another limitation is that the decision for statin usage was based on the clinical judgment of the treating physicians, which might produce a selective bias. Further, the significance of statin treatment is marginal, especially when considering the upper limit of the CI (HR 0.12, 95% CI 0.01-0.98). The marginally significant difference observed in statin usage between aPLpositive patients with and without thrombosis might be affected by the small number of patients in each group because multivariate analysis can be easily influenced by the sample size. One of the major limitations is that because of the study's retrospective design the statin-treated patients were different from the rest in several aspects. In aPL-positive patients treated with statins, the level of total cholesterol, LDL-cholesterol and the prevalence of hypertension and LN were statistically higher than in those without statins (Table 4) . However, long-term observation based on detailed clinical records was possible in this study design, leading to new evidence.
To our knowledge, this study is the first report to demonstrate that statins potentially prevent SLE patients with aPL from developing thrombosis. We believe that our study has given a clue to consider primary prophylaxis for thrombosis by statins. Prospective multicenter studies including large numbers of patients will confirm the beneficial role of statins.
In conclusion, this study confirmed that late SLE onset and the presence of IgG-aCL represent additional risk factors for thrombosis in SLE patients with aPL. Furthermore, our data suggest that statins at the early phase for aPL-positive SLE patients have a potential role against developing thrombosis.
